NICE update

Visit the NICE website

For more information on BSR's involvement with NICE contact the BSR Policy Officer Katy Lewis on klewis@rheumatology.org.uk.

---

Multiple Technology Appraisals

Psoriatic arthritis - etanercept, infliximab and adalimumab (review)

• BSR submitted comments on the final scope on 26 August 2009.

Rheumatoid Arthritis – drugs for treatment after failure of a TNF inhibitor

• This appraisal was re-started in November 2008, following the NICE Appeal Committee’s recommendation that NICE reconsider the issue of allowing patients prescription of an alternative anti-TNF if their first anti-TNF does not work satisfactorily.
• BSR submitted evidence on 10 August 2009.
• The first appraisal committee meeting will take place on 4 February 2010

Single Technology Appraisals

Abatacept - Juvenile idiopathic arthritis

• This technology appraisal was suspended, as the manufacturer of Abatacept was not in a position to submit evidence.

Certolizumab

• BSR submitted an organisational statement for this appraisal in June 2009.
• The first Appraisal Committee meeting took place on 23 September 2009, with the guidance expected to be issued in February 2010.
• The Appraisal Consultation Document was issued in October 2009. It did not recommend Certolizumab Pegol as a treatment option for people with rheumatoid arthritis. BSR sent comments on the ACD on 9th November. The finalised guidance is expected to be issued in February 2010.   

Denosumab

• BSR has registered as a consultee for this appraisal. The first Appraisal Committee meeting is taking place on 27th April 2010 and the guidance is expected to be issued, at the earliest, in September 2010.

   

Diacerein

• A scoping workshop is being held on 14th January 2010 on Diacerein for the treatment of osteoarthritis.

 

Febuxostat for the management of Hyperuricaemia in patients with Gout

• The NICE guidance was published in December 2008

Read NICE guidance on Febuxostat for the management of Hyperuricaemia in patients with Gout

Golimumab

• The three appraisals on Golimumab (for the treatment of rheumatoid arthritis after failure of previous antirheumatic drugs, for the treatment of rheumatoid arthritis (methotrexate-naïve) and for the treatment of ankylosing spondylitis) have all been suspended at the request of the manufacturer.

Rituximab

• A scoping workshop is being held on 15 January on Rituximab for the treatment of methotrexate-naive RA and of RA after the failure of DMARDs.

Tocilizumab

• The Appraisal Consultation document was issued in September 2009. It does not recommend Tocilizumab for the treatment of moderate to severe active rheumatoid arthritis.
• BSR commented on the ACD on 22 October. 

 

 

  

Clinical Guidelines

Low Back Pain
The Guidelines were issued in May 2009.
Read the NICE guidelines on early management of persistent non-specific low back pain

Osteoporosis

The Osteoporosis guidelines have been suspended

Rheumatoid Arthritis

The Guidelines were issued in February 2009.
Read the NICE guidelines on the management of rheumatoid arthritis in adults

Tuberculosis

BSR will participate in the revision of these guidelines

.